Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Mariska Sauzine Miranda
Observed names:
M Miranda,
Mariska Miranda,
Mariska S. Miranda
Institution:
QIMR Berghofer Medical Research Institute
Observed institutions:
Garvan Institute of Medical Research,
Queensland University of Technology,
The University of Queensland,
QIMR Berghofer Medical Research Institute,
The Kinghorn Cancer Centre,
Institute for Molecular Bioscience,
The University of Adelaide
show all 7
ORCID:
0009-0003-4435-9082
Observed ORCID:
0009-0003-4435-9082
OpenAlex ID:
A5109848836
Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer
2014
·
F Al-Ejeh
, P T Simpson
, et al.
·
Oncogenesis
·
114
PDF
Treatment of Triple-Negative Breast Cancer Using Anti-EGFR–Directed Radioimmunotherapy Combined with Radiosensitizing Chemotherapy and PARP Inhibitor
2013
·
Fares Al-Ejeh
, Wei Shi
, et al.
·
Journal of Nuclear Medicine
·
89
PDF
Kinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancer
2014
·
Fares Al-Ejeh
, Mariska Miranda
, et al.
·
Oncotarget
·
52
PDF
The CIMP Phenotype inBRAFMutant Serrated Polyps from a Prospective Colonoscopy Patient Cohort
2014
·
Winnie C. Fernando
, Mariska S. Miranda
, et al.
·
Gastroenterology Research and Practice
·
48
PDF
Gemcitabine and CHK1 Inhibition Potentiate EGFR-Directed Radioimmunotherapy against Pancreatic Ductal Adenocarcinoma
2014
·
Fares Al-Ejeh
, Marina Pajic
, et al.
·
Clinical Cancer Research
·
43
MEK5-ERK5 pathway associates with poor survival of breast cancer patients after systemic treatments
2015
·
Mariska Miranda
, Esdy Rozali
, et al.
·
Oncoscience
·
42
PDF
G9a-mediated repression of CDH10 in hypoxia enhances breast tumour cell motility and associates with poor survival outcome
2020
·
Francesco Casciello
, Fares Al-Ejeh
, et al.
·
Theranostics
·
41
PDF
Multidimensional phenotyping of breast cancer cell lines to guide preclinical research
2017
·
Jodi M. Saunus
, Chanel E. Smart
, et al.
·
Breast Cancer Research and Treatment
·
41
PDF
Essential Developmental, Genomic Stability, and Tumour Suppressor Functions of the Mouse Orthologue of hSSB1/NABP2
2013
·
Wei Shi
, Amanda L. Bain
, et al.
·
PLoS Genetics
·
38
PDF
Overexpression of miRNA-25-3p inhibits Notch1 signaling and TGF-β-induced collagen expression in hepatic stellate cells
2019
·
Berit Genz
, Miranda A. Coleman
, et al.
·
Scientific Reports
·
35
PDF
Secreted cellular prion protein binds doxorubicin and correlates with anthracycline resistance in breast cancer
2019
·
Adrian P. Wiegmans
, Jodi M. Saunus
, et al.
·
JCI Insight
·
33
RAD51 inhibition in triple negative breast cancer cells is challenged by compensatory survival signaling and requires rational combination therapy
2016
·
Adrian P. Wiegmans
, Mariska Miranda
, et al.
·
Oncotarget
·
32
PDF
Erratum: Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer
2014
·
F Al-Ejeh
, P T Simpson
, et al.
·
Oncogenesis
·
30
PDF
Combined Inhibition of G9a and EZH2 Suppresses Tumor Growth via Synergistic Induction of IL24-Mediated Apoptosis
2022
·
Francesco Casciello
, Gregory M. Kelly
, et al.
·
Cancer Research
·
28
Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer
2022
·
Jodi M. Saunus
, Xavier M. De Luca
, et al.
·
npj Breast Cancer
·
24
PDF
Effects of silibinin on growth and invasive properties of human ovarian carcinoma cells through suppression of heregulin/HER3 pathway
2015
·
Majid Momeny
, Reza Ghasemi
, et al.
·
Tumor Biology
·
16
Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
2025
·
Michelle Melino
, Wen Juan Tu
, et al.
·
Molecular Cancer Therapeutics
·
11
PDF
ERK5 Mediates Metastatic Colonization and Remodeling of The Tumor and Tumor-Immune Microenvironment and Immunotherapy Response
2025
·
Mariska Miranda
, Oishee Chatterjee
, et al.
·
Fortune Journal of Health Sciences
·
1
Supplementary Results from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
2025
·
Michelle Melino
, Wen Juan Tu
, et al.
Supplementary Figure 5 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
2025
·
Michelle Melino
, Wen Juan Tu
, et al.
PDF
Supplementary Figure 1 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
2025
·
Michelle Melino
, Wen Juan Tu
, et al.
PDF
Supplementary Figure 2 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
2025
·
Michelle Melino
, Wen Juan Tu
, et al.
PDF
Supplementary Figure 4 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
2025
·
Michelle Melino
, Wen Juan Tu
, et al.
PDF
Data from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
2025
·
Michelle Melino
, Wen Juan Tu
, et al.
Supplementary Table S3 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
2025
·
Michelle Melino
, Wen Juan Tu
, et al.
PDF
Show more works
View as search
Works count:
51
Citation count:
718
H-index:
16
I10-index:
17
Year
Topic
Type